8-K filing — ACTUATE THERAPEUTICS, INC. (ACTU)
Filed: 2026-10-28 AccNo: 0001683168-26-008143 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
Actuate Therapeutics, Inc. has priced an underwritten public offering of its securities to raise $11.0 million in gross proceeds.
Actuate Therapeutics shares are trading higher after the company announced a public offering of 40 million shares and 20 million warrants.
Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.